CDMO News
Bora Biologics Partners with DotBio to Develop Novel Tri-Specific Antibody
Bora Biologics, a growing division of contract development and manufacturing organisation (CDMO) Bora Pharmaceuticals, has announced its collaboration with DotBio, a Singaporean biopharmaceutical company. Bora will assist in the development and manufacturing of DotBio’s lead asset, DB007, a tri-specific antibody
9 January 2025